Transapical transcatheter valve-in-valve implantation for failed mitral valve bioprosthesis

Eyal R. Nachum, Ehud Raanani, Amit Segev, Victor Guetta, Ilan Hai, Amihai Shinfeld, Paul Fefer, Hamdan Ashraf, Israel Barabash, Amjad Shalabi, Dan Spiegelstein*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Background: The rate of mitral bioprosthesis implantation in clinical practice is increasing. Transcatheter valve-invalve implantation has been described for high risk patients requiring redo valve surgery. Objectives: To report our experience with transapical valve-invalve implantation for failed mitral bioprosthesis. Methods: Since 2010, 10 patients have undergone transapical valve-in-valve implantation for failed bioprosthesis in our center. Aortic valve-in-valve implantation was performed in one of them and mitral valve-in-valve implantation in nine. Mean age was 82 ± 4 years and 6 were female (67%). Mean time from original mitral valve (MV) replacement to valve-in-valve procedure was 10.5 ± 3.7 years. Follow-up was completed by all patients with a mean duration of 13 ± 12 months. Results: Preoperatively, all patients presented with significant mitral regurgitation, two with mitral stenosis due to structural valve failure. All nine patients underwent successful transapical valve-in-valve implantation with an Edwards Sapien™ balloon expandable valve. There was no in-hospital mortality. Mean and median hospital duration was 15 ± 18 and 7 days respectively. Valve implantation was successful in all patients and there were no major complications, except for major femoral access bleeding in one patient. At last follow-up, all patients were alive and in NYHA functional class I or II. Echocardiography follow-up demonstrated that mitral regurgitation was absent or trivial in seven patients and mild in two. At follow-up, peak and mean gradients changed from 26 ± 4 and 8 ± 2 at baseline to 16.7 ± 3 and 7.3 ± 1.5, respectively. Conclusions: Transcatheter transapical mitral valve-in-valve implantation for failed bioprosthesis is feasible in selected high risk patients. Our early experience with this strategy is encouraging. Larger randomized trials with long-term clinical and echocardiographic follow-up are recommended.

Original languageEnglish
Pages (from-to)13-17
Number of pages5
JournalIsrael Medical Association Journal
Issue number1
StatePublished - Jan 2016


  • Minimally invasive surgery
  • Mitral bioprosthesis
  • Transapical valve implantation
  • Transcatheter aortic valve implantation (TAVI)
  • Valve in valve


Dive into the research topics of 'Transapical transcatheter valve-in-valve implantation for failed mitral valve bioprosthesis'. Together they form a unique fingerprint.

Cite this